Box 1.
Important immune checkpoint inhibitors
Anti-PD-1/anti-PD-L1 inhibitors
Nivolumab
Pembrolizumab
Atezolizumab
Avelumab
Durvalumab
Anti-CTLA-4 inhibitors
Ipilimumab
Tremelimumab